ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Vasculitis"

  • Abstract Number: PP02 • ACR Convergence 2020

    Low- and Hi-Tech Tools for Enhancing Patient-Hospital Care Team Communication in the Context of Rare Disease

    Ida Hakkarinen1, 1Vasculitis Patient-Powered Research Network (VPPRN) / Member, Vasculitis Foundation, Greenbelt, MD

    Background/Purpose: For over two years, I experienced a variety of disparate symptoms including:  joint aches, sinus congestion, shortness of breath and chronic cough. An episode…
  • Abstract Number: 0403 • ACR Convergence 2020

    Comparison of Immediate Post-Operative and Long-Term Outcomes in Aortitis and Non-Inflammatory Thoracic Aortic Aneurysms Undergoing Open Surgical Repair

    Adam Mayer1, Alexandra Sperry2, Laarni Quimson3 and Rennie Rhee4, 1University of Pennsylvania, Internal Medicine/Pediatrics Residency Program, Philadelphia, PA, 2Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 3Division of Rheumatology at the University of Chicago, Chicago, IL, 4University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Around 2-12% of patients who undergo open thoracic aortic aneurysm repair are incidentally found to have aortitis on pathology.  There is no standardized approach…
  • Abstract Number: 0511 • ACR Convergence 2020

    ERAP1-mediated Immunogenicity and Immune-phenotypes in HLA-B51+ Behçet’s Disease Point to Pathogenic CD8 T Cell Effector Responses

    Ann Cavers1, Yesim Ozguler2, Olivier Manches3, Arshed Al-Obeidi1, Hua Zhong1, Beatrix Ueberheide1, Gülen Hatemi4, Matthias Kugler1 and Johannes Nowatzky5, 1NYU School of Medicine, New York, 2Istanbul University Cerrahpaşa Medical School, Istanbul, Turkey, 3Inserm, U 1209, Grenoble, France, 4Istanbul University‒Cerrahpaşa, Cerrahpaşa Medical School and Behçet’s Disease Research Center, Istanbul, Turkey, 5New York University School of Medicine, New York, NY

    Background/Purpose: HLA-B51 is a definite risk factor for Behçet’s disease (BD). A coding variant of ERAP1, Hap10 – with low peptide-trimming activity – vastly potentiates…
  • Abstract Number: 1434 • ACR Convergence 2020

    The Role of Sural Nerve Biopsy in the Diagnosis of Systemic Vasculitis – a Retrospective Study from Two Specialized Centres

    Karl Gisslander1, Lars Dahlin2, Rona Smith3, David Jayne3 and Aladdin Mohammad4, 1Lund University, Lund, Sweden, Lund, Sweden, 2Department of Translational Medicine – Hand Surgery, Lund University, Malmö, Sweden, Malmö, Sweden, 3Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Cambridge, United Kingdom, 4Lund University, Lund, Sweden. Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Lund, Sweden

    Background/Purpose: Vasculitis of the peripheral nervous system is seen mainly in systemic vasculitis involving small and medium sized vessels and in cases of single-organ vasculitis…
  • Abstract Number: 1925 • ACR Convergence 2020

    Ultrasound Follow-up Examination of Intima-Media-Thickness of the Temporal and Axillary Artery over Six Months in Patients with Newly Diagnosed Giant Cell Arteritis

    Lara Burg1, Peter Brossart2, Charlotte Behning3 and Valentin Schaefer4, 1Clinic for Internal Medicine III, Department of Oncology, Haematology, Rheumatology and Clinical Immunology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, 2Clinic for Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, 3Institute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, 4Clinic of Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany

    Background/Purpose: Ultrasound (US) plays an important role in diagnosis of giant cell arteritis (GCA). To date it is unknown how intima-media-thickness (IMT) of affected arteries…
  • Abstract Number: PP03 • ACR Convergence 2020

    Connecting with Rheumatology Professionals and Thought Leaders Inspired the Creation of a New Program Focused on Relapsing Polychondritis (“RP”), a Rare Rheumatic Disease: Participating at ACR Annual Meetings Has Provided Exceptional Opportunities to Learn and Build Relationships

    Nancy Linn1, Catherine Bammert2, David Bammert3 and Michael Linn4, 1Relapsing Polychondritis Foundation, Palos Verdes Estates, CA, 2MD Anderson, Houston, TX, 3Relapsing Polychondritis Foundation, Houston, TX, 4Relapsing Polychondritis Foundation, New York, NY

    Background/Purpose: In 2011, I was diagnosed with relapsing polychondritis ("RP"), a debilitating and sometimes fatal rheumatic disease that is characterized by inflammation of cartilage and…
  • Abstract Number: 0404 • ACR Convergence 2020

    Isolated Aortitis: Single Centre Experience of Clinical Spectrum and Management

    Nadia Ahmad1, Ayna Verdiyeva2, Raashid Luqmani2 and Shirish Dubey2, 1Oxford University Hospitals NHS Foundation Trust, Reading, United Kingdom, 2Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

    Background/Purpose: Aortitis was previously regarded as a rare form of large vessel vasculitis (LVV), but is now increasingly being recognised. It may occur in the…
  • Abstract Number: 0514 • ACR Convergence 2020

    Feasibility of 18F-fluorodeoxyglucose Positron Emission Tomography to Monitor the Effect of Tocilizumab on Vascular Inflammation in Giant Cell Arteritis: A Prospective Observational Cohort Study

    Kaitlin Quinn1, Himanshu Dashora2, Mark Ahlman3, Elaine Novakovich2 and Peter C. Grayson2, 1Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, 2Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD, 3National Institutes of Health, Clinical Center, Radiology and Imaging Sciences, Bethesda, MD

    Background/Purpose: Two randomized controlled trials have demonstrated the clinical efficacy of tocilizumab for treatment of giant cell arteritis (GCA) (1,2).  In these trials, response to…
  • Abstract Number: 1435 • ACR Convergence 2020

    Prognostic Factors for Mononeuritis Multiplex Associated with ANCA-associated Vasculitis

    Yutaro Hayashi1, Satoshi Hama2, Keisuke Izumi2, Mari Ushikubo1, Misako Konishi3, Yutaka Okano4 and Hisaji Ohshima2, 1Tokyo medical center, Tokyo, Japan, 2Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, tokyo, Japan, 3Tokyo medical center, toukyouto Meguroku, Japan, 4Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, Kawasaki, Japan

    Background/Purpose: ANCA-associated vasculitis (AAV) sometimes presents mononeuritis multiplex which worsens the prognosis and activity of daily living in patients. This study aimed to determine theprognostic factorsand…
  • Abstract Number: 1928 • ACR Convergence 2020

    Quantitative Ultrasound of Temporal, Axillary and Subclavian Arteries to Monitor Tocilizumab Treatment in Patients with Newly Diagnosed Giant Cell Arteritis: A 24 Week Analysis

    Luca Seitz1, Lisa Christ1, Godehard Scholz1, Fabian Lötscher1, Jennifer Amsler1, Florian Kollert1, Stephan Reichenbach1 and Peter Villiger1, 1Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Switzerland, Bern, Switzerland

    Background/Purpose: Tocilizumab (TCZ) suppresses CRP. Thus, CRP cannot be used as a marker for disease activity in GCA patients treated with TCZ and monitoring of…
  • Abstract Number: 0406 • ACR Convergence 2020

    Infliximab in Refractory Uveitis Due to Behçet’s Disease: Long Term Follow-up and Therapy Optimization. Multicenter Study of 103 Caucasian Patients

    José Luis Martín-Varillas1, Belén Atienza-Mateo2, Vanesa Calvo-Río3, Emma Beltran-Catalan4, Alfredo Adan5, Marisa Hernandez Garfella6, Elia Valls-Pascual7, Agustín Sellas-Fernández8, N Ortego9, Alejandro Fonollosa10, Olga Maiz Alonso11, Ignacio Torre12, Cruz Fernández-Espartero13, Vega Jovani14, Diana Peiteado15, David Díaz Valle16, Susana Romero-Yuste17, Elena Aurrecoechea1, Miriam García-Arias18, Miguel Ángel Caracuel19, Santos Insúa20, Senén González-Suárez21, Amalia Sánchez Andrade22, Luis Francisco Linares23, Alfredo J García González24, Raquel Almodovar25, Carmen Carrasco Cubero26, María Alcalde Villar27, C Fernandez-Carballido28, Fred A Pages29, Eva Peña Sainz-Pardo24, Rosalia Demetrio-Pablo3, Santos Castañeda30, Miguel Ángel González-Gay31, José Luis Hernández3 and Ricardo Blanco3, 1Hospital Sierrallana, Torrelavega, Spain, 2Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3Hospital Universitario Marques de Valdecilla, Santander, Spain, 4Del Mar University Hospital, Barcelona, 5Hospital Clinic, Barcelona, Catalonia, Spain, 6H. Valencia, Valencia, Spain, 7H. Doctor Peset, Valencia, Spain, 8H. Vall d'Hebron, Barcelona, Spain, 9H. San Cecilio, Granada, Spain, 10H. de Cruces, Bilbao, Spain, 11Hospital Universitario Donostia, San Sebastian, Pais Vasco, Spain, 12Hospital Basurto, Bilbao, Spain, 13H. Mostoles, Madrid, Spain, 14H. Alicante, Alicante, Spain, 15Hospital La Paz - IdiPAZ, Madrid, Spain, 16H. Clínico San Carlos, Madrid, Spain, 17H Pontevedra, Coruna, Spain, 18H. La Princesa, Madrid, 19H.U. Reina Sofía, Córdoba, Spain, 20H. Santiago de Compostela, Santiago de Compostela, Spain, 21H. Cabueñes, Gijón, Spain, 22H. Lucus Augusti, Lugo, Spain, 23Hospital de la Arrixaca, Murcia, 24H. 12 de Octubre, Madrid, Spain, 25Fundación Alcorcón University Hospital, Madrid, 26H. Mérida, Mérida, Spain, 27H. Severo Ochoa, Madrid, Spain, 28H San Juan, Alicante, Spain, 29H. Palencia, Palencia, Spain, 30Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, 31Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

    Background/Purpose: Biologic therapy has improved prognosis of Behçet Disease (BD) uveitis. Although infliximab (IFX) is approved in Japan, most data in Caucasian patients comes from…
  • Abstract Number: 0517 • ACR Convergence 2020

    Trends in the Incidence and Use of Diagnostic Modalities for Giant Cell Arteritis over Seven Decades: A Population-based Study

    Thomas Garvey1, Cynthia Crowson2, Matthew J. Koster3 and Kenneth Warrington3, 1Mayo Clinic Rochester, Apple Valley, MN, 2Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, 3Mayo Clinic, Rochester, MN

    Background/Purpose: Diagnostic methods for giant cell arteritis (GCA) have evolved over recent decades, and large vessel imaging plays an increasing role in disease detection.   The…
  • Abstract Number: 1438 • ACR Convergence 2020

    Rituximab Immunogenicity in ANCA-associated Vasculitis (RITUXIMAV)

    Jason Springer1 and Ryan Funk2, 1University of Kansas Medical Center, Overland Park, KS, 2UNIVERSITY OF KANSAS, Kansas City, KS

    Background/Purpose: Rituximab (RTX), an anti-CD20 chimeric monoclonal antibody, has been shown to be an effective maintenance therapy for granulomatosis with polyangitiis (GPA) and microscopic polyangiitis…
  • Abstract Number: 1931 • ACR Convergence 2020

    Effect of Cumulative Glucocorticoid Dose and Inflammation on Weight Change During Treatment of Giant Cell Arteritis

    Naomi Serling-Boyd1, Xiaoqing Fu2, Yuqing Zhang3, Sebastian Unizony1, Zachary Wallace4, Hyon Choi5 and John H. Stone6, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Boston, 3Massachusetts General Hospital, Quincy, MA, 4Massachusetts General Hospital, Newton, MA, 5Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA, 6Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA

    Background/Purpose: Giant cell arteritis (GCA) is a form of large vessel vasculitis that requires treatment with high-dose, long-term glucocorticoids (GC). Weight gain, among other side-effects…
  • Abstract Number: 0409 • ACR Convergence 2020

    Clinical Characteristics, Brain MRI Findings, and Diagnostic Approach of the Central Nervous System Vasculitis by Affected Vessel Size

    Takashi Shimoyama1, Ken Uchino2, Leonard Calabrese3 and Rula Hajj-ali3, 1Nippon Medical School, Nippon, Japan, 2Cleveland Clinic, Cleveland, 3Cleveland Clinic, Cleveland, OH

    Background/Purpose: Diagnosis of the central nervous system vasculitis (CNS-V) is made on the basis of image findings or brain biopsy. Recently, two different subtypes of…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 13
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies